Mr. Todd Shapiro reports

RHELION LIFE SCIENCES' WHOLLY OWNED SUBSIDIARY FILAMENT HEALTH ISSUED NEW UNITED STATES PATENT, EXTENDING THE BROADEST NATURAL PSILOCYBIN PATENT ESTATE

Through Rhelion Life Sciences Corp.'s wholly owned subsidiary, Filament Health Corp., the company develops, manufactures and supplies PEX010, its patented, standardized, GMP (good manufacturing practice) manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide.

The company is pleased to announce that the United States Patent and Trademark Office has issued a new patent to Filament, titled "Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids."

The grant adds to what the company believes is the most extensive patent estate in natural psilocybin, spanning issued patents across the United States, Canada, Australia, Israel, Mexico and Europe, and covering extraction, purification, stabilization, standardized compositions and delivery.

That estate is what sits behind PEX010. PEX010 is produced using Filament's proprietary and patented extraction, purification and stabilization methods and is available in a standardized dosing range of one, five and 25 milligrams from a single drug candidate, with a 0.5 mg dose to follow, giving investigators consistent composition across every dose, every study and every research site.

"We acquired Filament not just for PEX010, the team and the distribution network, but for the patents underneath all of it," said Todd Shapiro, chief executive officer and director of Rhelion. "There is a lot of talk in this sector about proprietary methods. Filament's are the ones actually backed by patents, and those patents protect how the drug candidate is made, at scale, to GMP, for researchers who need the same product dose after dose. That is the real asset in the natural psychedelics space."

PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide. On April 30, 2026, the company completed its previously announced acquisition of Filament Health, including its lead drug candidate, PEX010, and its patent portfolio, which now stands at 77 issued patents across 13 patent families following this grant.

About Rhelion Life Sciences Corp.

Rhelion Life Sciences is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health, the company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.

We seek Safe Harbor.